Cingapura - inglês - HSA (Health Sciences Authority)

intega pte ltd - erlotinib hydrochloride eqv erlotinib - tablet, film coated - erlotinib hydrochloride eqv erlotinib 100.00mg

Cingapura - inglês - HSA (Health Sciences Authority)

intega pte ltd - erlotinib hydrochloride eqv erlotinib - tablet, film coated - erlotinib hydrochloride eqv erlotinib 150.00mg

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - erlotinib hydrochloride, quantity: 163.93 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - erlotinib hydrochloride, quantity: 109.29 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - erlotinib hydrochloride, quantity: 27.32 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium lauryl sulfate; sodium starch glycollate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Estados Unidos - inglês - NLM (National Library of Medicine)

areva pharmaceuticals - erlotinib hydrochloride (unii: da87705x9k) (erlotinib - unii:j4t82ndh7e) - erlotinib tablets was indicated for: - the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen [see clinical studies (14.1, 14.3)]. limitations of use: - safety and efficacy of erlotinib have not been established in patients with nsclc whose tumors have other egfr mutations [see clinical studies (14.1, 14.2)] . - erlotinib tablet is not recommended for use in combination with platinum-based chemotherapy [see clinical studies (14.4)] . erlotinib tablet in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer [see clinical studies (14.5)] . none risk summary based on animal data and its mechan

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

alchemy health limited - erlotinib hydrochloride 27.32mg equivalent to erlotinib 25mg - film coated tablet - 25 mg - active: erlotinib hydrochloride 27.32mg equivalent to erlotinib 25mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 200f280000 sodium starch glycolate - erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib is also indicated for the treatment of patients with locally advanced or metastatic nsclc who have previously received chemotherapy.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

alchemy health limited - erlotinib hydrochloride 54.63mg equivalent to erlotinib 50mg - film coated tablet - 50 mg - active: erlotinib hydrochloride 54.63mg equivalent to erlotinib 50mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 200f280000 sodium starch glycolate - erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib is also indicated for the treatment of patients with locally advanced or metastatic nsclc who have previously received chemotherapy.

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - erlotinib hydrochloride -

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - erlotinib hydrochloride -